Randomized Trials of Retosiban Versus Placebo or Atosiban in Spontaneous Preterm Labor. by Saade, G et al.
 
1 
Randomized trials of retosiban versus placebo or atosiban in spontaneous preterm 
labor 
George Saade MDa, Andrew Shennan MDb, Kathleen J Beach MDc,1, Eran Hadar MDd, 
Barbara V Parilla MDe,2, Jerry Snidow PharmDf,3, Marcy Powell MDg, Timothy H Montague 
PhDh, Feng Liu PhDh,4, Yosuke Komatsu MDi,5, Laura McKain MDj,6, Steven Thornton DMk 
aDepartment of Obstetrics and Gynecology, University of Texas Medical Branch, Galveston, 
TX, USA; bDepartment of Women and Children’s Health, King’s College London, St 
Thomas’ Hospital, London, UK; cDepartment of Maternal and Fetal Medicine, GSK, 
Research Triangle Park, NC, USA; dHelen Schneider Hospital for Women, Rabin Medical 
Center, Petach-Tikva, Israel and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, 
Israel; eDepartment of Obstetrics and Gynecology, Advocate Lutheran General Hospital, Park 
Ridge, IL, USA; fAlternative Discovery and Development, GSK, Research Triangle Park, 
NC, USA; gCentral Safety Department, GSK, Research Triangle Park, NC, USA; hClinical 
Statistics, Quantitative Sciences, GSK, Collegeville, PA, USA; iMaternal and Neonatal 
Health Unit, Alternative Discovery & Development, R&D, GSK, Research Triangle Park, 
NC, USA; jPharmacovigilance, PPD, Wilmington, NC, USA; kBarts and The London School 
of Medicine and Dentistry, Queen Mary University of London, London, UK 
1At the time of the trial; 2At the time of the trial, present address: Rush Center for Maternal-
Fetal Medicine, Aurora, IL, USA; 3At the time of the trial; 4At the time of the trial, present 
address: AstraZeneca, Gaithersburg, MD, USA, 5At the time of the trial, present address: 
Clinical Development, Ferring Pharmaceuticals, Parsippany, NJ, USA; 6At the time of the 
trial, present address: Myovant Sciences, Brisbane, CA, USA 
Corresponding Author: Professor George Saade, MD 
 
2 
Department of Obstetrics and Gynecology, The University of Texas Medical Branch, 301 
University Blvd, Galveston, TX, 77555, USA 
E-mail: gsaade@utmb.edu 
Tel: +1 409 747 0482 
Fax: +1 409 772 5297 
Abstract Word Count: 300 (max 300) 
Main Text Word Count: 3225 




Abstract (299/300 words) 
OBJECTIVE: To assess the efficacy and safety of retosiban in spontaneous preterm labor.  
STUDY DESIGN: Two multicenter, randomized, double-blind trials compared retosiban 
with placebo and retosiban with atosiban in women with a singleton pregnancy and intact 
membranes in spontaneous preterm labor at 24–336/7 weeks’ gestation. Coprimary endpoints 
in the placebo-controlled trial were time to delivery (TTD) or treatment failure (whichever 
occurred first) and neonatal composite morbidity and mortality. The primary endpoint of the 
atosiban comparator trial was TTD.  
RESULTS: The trials were terminated early because of slow recruitment. The placebo-
controlled trial enrolled 23 participants (February 2016–July 2017; 2.6% of target); the 
atosiban-comparator trial enrolled 97 (March 2015–August 2017; 29% of target). Baseline 
participant characteristics were similar between treatments. In the placebo-controlled trial, 
mean gestational ages at randomization were 30.8 (retosiban, n=10) and 30.5 weeks (placebo, 
n=13), and mean times to delivery/treatment failure were 18.9 days (retosiban) and 11.1 days 
(placebo). Two and four neonates in the retosiban and placebo groups, respectively, had ≥1 
component of the neonatal composite endpoint. In the atosiban-comparator trial, mean 
gestational age at randomization was 31.5 weeks (for both retosiban, n=47, and atosiban, 
n=50), and adjusted mean TTDs were 32.51 days (retosiban) and 33.71 days (atosiban; 
P>0.05). Adverse events were no more common with retosiban than placebo or atosiban.  
CONCLUSION: Despite considerable efforts to conduct two adequate and well-controlled 
studies in patients with spontaneous preterm labor, both studies were unable to recruit 
effectively and consequently terminated prematurely. Key factors negatively affecting 
participation were patient and physician resistance to use of a placebo comparator, lack of 
investigator consensus on diagnostic criteria and acceptance of protocol procedures, and 
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ethics committee decisions. Meaningful cooperation between pharmaceutical companies, 
regulatory authorities, and the obstetric community is essential for future development of 
drugs to treat spontaneous preterm labor. 
Key words: atosiban, efficacy, oxytocin antagonist, recruitment, retosiban, safety, 





Successful development and regulatory approval of treatments for preterm labor have been 
sparse for 4 decades owing to safety/liability concerns of experimental drugs, regulatory 
requirements to demonstrate neonatal benefit, changes in clinical management of preterm 
labor, and the complexity of developing protocols that address these issues.1 Several areas 
central to tocolytic drug development include the feasibility of placebo-controlled trials, 
identifying appropriate study endpoints and time frames, and ensuring collaboration between 
the Food and Drug Administration (FDA) and other parties.1 
In the United States (US), there are no FDA-approved tocolytics1, 2; atosiban has been 
approved by the European Medicines Agency (EMA).3 Globally, indomethacin, beta-
mimetics, calcium channel blockers, and magnesium sulfate are used off-license.4 However, 
these lack convincing evidence for improvement in neonatal outcomes5, 6 and may have 
undesirable fetal and maternal side effects.7, 8  
Retosiban, a selective oxytocin receptor antagonist, was associated with a >1-week increase 
in time to delivery (TTD) versus placebo and a significant reduction in preterm birth, with no 
safety issues, in a phase 2 trial.2  
Two randomized trials were conducted in women with spontaneous preterm labor (sPTL) to 
assess the efficacy and safety of retosiban versus placebo or atosiban; however, the trials 
were terminated early because of slow recruitment. Here we present the key findings of both 
studies at trial termination (before calculated sample sizes were reached), review key factors 
that affected participation, and discuss the challenges of conducting tocolytic trials. 
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Materials and Methods 
Trial designs 
The placebo-controlled trial was a phase 3, randomized, double-blind, parallel-group, 
multicenter trial of retosiban versus placebo in participants with sPTL. The atosiban 
comparator trial was a multicenter, randomized, double-dummy, double-blind, phase 3 trial 
of retosiban versus atosiban in participants with sPTL.  
Eligible participants were randomized (1:1; Supplementary Material 1) to a 48-hour infusion 
of assigned treatment. Participants who remained undelivered were assessed 48 hours post-
treatment, then contacted weekly until delivery. Maternal delivery and hospitalization records 
were reviewed by the investigator upon delivery. All participants were contacted within 6 
weeks of delivery for assessment, and neonatal records from delivery to 28 days after the 
estimated date of delivery (EDD; 40 weeks’ gestation) were reviewed by a neonatologist.  
Concomitant tocolytic therapy was prohibited. Participants were eligible for the placebo-
controlled trial if: no tocolytic treatment had been initiated before consent; a protocol-
prohibited tocolytic was stopped before randomization; tocolytic treatment was given in a 
prior sPTL episode (current pregnancy); or they were receiving magnesium sulfate (and all 
other eligibility criteria were met). Participants were eligible for the atosiban comparator trial 
if they had not received any tocolytic or had received but not responded to a tocolytic other 
than atosiban during their current sPTL episode. Participants were excluded if they had 
contraindications to tocolytic therapy. Full exclusion criteria and stopping rules are described 
in Supplementary Material 2.  
Antenatal corticosteroids (betamethasone or dexamethasone) were given. Magnesium sulfate 
and intrapartum antibiotic prophylaxis were permitted at the investigator’s discretion, 
following local guidelines. 
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There were no a priori rules for trial termination. Termination was at the discretion of the 
sponsor, with an independent data monitoring committee able to recommend termination 
following interim analyses.  
Trial populations 
Participants were aged 12–45 years (lower age limit based on prior regulatory discussions 
with the FDA and EMA) with an uncomplicated singleton pregnancy and intact membranes 
in sPTL, defined as: regular uterine contractions confirmed by tocodynamometry (≥4 
contractions of ≥30 seconds’ duration during 30 minutes), and cervical dilation ≥2–≤4 cm by 
digital examination or, if <2 cm, cervical change consistent with a 10-mm decrease in 
cervical length by transvaginal ultrasound or an absolute increase of ≥25% in effacement by 
cervical digital examination or a 1-cm increase in cervical dilation. Participants were at 240/7–
336/7 weeks’ gestation, confirmed/determined by known fertilization date (in vitro 
fertilization/intrauterine insemination) or EDD (ultrasound before 240/7 weeks’ gestation). 
Treatments 
In both trials, participants were stratified by progesterone treatment (established progesterone 
therapy vs not) and gestational age (240/7–256/7, 260/7–276/7, 280/7–306/7, or 310/7–336/7). In the 
placebo-controlled trial, participants were randomized to intravenous (IV) retosiban infusion 
over 48 hours or matching placebo. Retosiban was administered as a 6-mg loading dose over 
5 minutes followed by a 6-mg/h infusion for the remainder of the treatment period.  
In the atosiban comparator trial, participants were randomized to IV infusion over 48 hours 
with either retosiban+matching placebo atosiban or atosiban+matching placebo retosiban. 
Retosiban was administered as described above. Atosiban was administered as a 6.75-mg 
loading dose over 1 minute followed by an 18-mg/h infusion for 3 hours, after which the 
infusion rate was reduced to 6 mg/h for the remainder of the treatment period. Placebo 
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infusions in both trials (0.9% sodium chloride) were matched for the loading dose, and 
subsequent infusion rates were matched for the treatment period.  
In both trials, if there was an inadequate response in contraction frequency/intensity or 
cervical dilation after the first hour of treatment, another 6-mg dose of retosiban (or placebo) 
was given over 5 minutes, after which retosiban or placebo was given at 12 mg/h.  
No additional study treatment doses were permitted in the placebo-controlled trial. In the 
atosiban comparator trial, additional doses of study treatment could be given, at the 
investigator’s discretion, to participants with recurrent sPTL ≥24 hours after completing the 
specified treatment regimen and who still met eligibility criteria. 
Infusions and matching placebos were prepared by unblinded pharmacists/qualified 
individuals. Participants and all other personnel were blinded for the study duration.  
Ethical approval and data availability 
Trials were conducted in accordance with the International Council for Harmonisation for 
Good Clinical Practice and country-specific requirements. Study protocols were approved by 
the ethics committee or institutional review board at each study center, and are available at 
www.clinicaltrials.gov (NCT02377466 and NCT02292771). An independent data-monitoring 
committee monitored maternal, fetal, and neonatal unblinded data throughout the trial. An 
internal GSK safety review team monitored blinded safety data. All participants provided 
written informed consent.  
Objectives and endpoints 
The objectives were to demonstrate superiority of retosiban in prolongation of pregnancy 




The placebo-controlled trial had a coprimary endpoint of TTD or treatment failure (use of a 
rescue tocolytic), whichever occurred first, and an a priori neonatal composite endpoint of 
mortality and morbidity outcomes up to 28 days after the EDD (Supplementary Material 3).9, 
10 Key secondary endpoints included TTD and proportion of births before 37 weeks’ 
gestation.  
The primary endpoint of the atosiban comparator trial was TTD. Key secondary endpoints 
included proportion of births before 37 weeks’ gestation, proportion of births at term (37–
416/7 weeks’ gestation), and proportion of neonates with any diagnosis from the neonatal 
morbidity or mortality composite endpoint. 
In both trials, safety assessments included maternal, fetal, and neonatal adverse events (AEs), 
maternal vital signs, fetal heart rate assessments, baseline electrocardiogram, and clinical 
laboratory tests. Pharmacokinetic assessments included blood, umbilical cord, and breast 
milk retosiban concentrations. Other endpoints are listed in Supplementary Material 3. 
Statistical analyses  
The recruitment target for the placebo-controlled trial was 900 participants to provide 86% 
power to detect a 32% relative risk reduction between retosiban and placebo in neonatal 
outcomes and an average difference of 5.5 days in TTD or treatment failure, assuming an 
incidence of 23% for retosiban and 34% for placebo, allowing for interim analysis (planned 
at 150 and 400 deliveries).  
Recruitment target for the atosiban comparator trial was 330 participants, to provide 86% 
power to detect an average difference of 9.5 days between retosiban and atosiban in TTD. 
Interim analysis was planned at 130 deliveries. For both trials, calculations were based on 
simulations using assumptions based on real-world data and a 2-sided testing procedure with 
a ~10% dropout rate. 
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Data are presented for the intent-to-treat population, comprising all participants who received 
study drug and their infants.  
Because of the early trial termination and resultant small sample size, no statistical analysis 
was conducted for the placebo-controlled trial. The coprimary endpoints are summarized 
using descriptive statistics. The prospectively planned analyses are listed in Supplementary 
Material 4.  
The primary endpoint in the atosiban comparator trial was analyzed using a 2-component 
normal mixture model. Within each component, expected TTD was modeled as a function of 
treatment as a fixed effect, and gestational age at randomization and established progesterone 
use as covariates. Point estimates of the treatment means and standard deviation (SD) were 
calculated, along with the estimate of mean treatment difference (retosiban−atosiban), 
corresponding 95% confidence intervals (CIs), and P-values. Time to delivery by treatment 
was presented in a Kaplan–Meier plot. Key secondary endpoints (Supplementary Material 4) 
were not analyzed.  
All analyses were performed using SAS version 9.3 (SAS Institute Inc., Cary, NC, USA). 
Results 
Study sites, participant disposition, and characteristics 
Of 607 centers approached for the placebo-controlled trial, 46 centers in 5 countries agreed to 
recruit (Supplementary Material 5) and 10 centers enrolled participants between February 
2016 and July 2017. Screening failures were high: 1% of participants met eligibility criteria. 
Twenty-five participants were randomized, and 23 received treatment (10 retosiban, 13 
placebo; Figure 1).   
Of 343 centers approached in the atosiban comparator trial, 48 centers in 10 countries agreed 
to participate (Supplementary Material 5), with 23 centers enrolling participants between 
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March 2015 and August 2017. Screening failure rates were high: 6% of participants met 
eligibility criteria. One hundred participants were randomized and 97 received treatment (47 
retosiban, 50 atosiban; Figure 2).  
There was no overlap in the centers enrolling for each study (Supplementary Material 5). 
In both trials, baseline maternal and fetal demographics and clinical characteristics were 
similar between treatment groups (Tables 1 and 2).  
Treatment 
In the placebo-controlled trial, 3 (30.0%) participants in the retosiban group required a dose 
increase versus 10 (76.9%) in the placebo group. Three (30.0%) participants in the retosiban 
group and 5 (38.5%) in the placebo group discontinued treatment. This was because of an 
inadequate response in contraction frequency/intensity or cervical dilation in 2 retosiban-
treated and 4 placebo-treated participants.  
In the atosiban comparator trial, 17 (36.2%) retosiban-treated participants versus 23 (46.0%) 
atosiban-treated participants received an increased dose. Eight participants in each group 
discontinued treatment; 5 in each group owing to an inadequate therapeutic response, 3 to 
AEs (retosiban: n=1 maternal, n=1 fetal; atosiban: n=1 maternal), and 1 each owing to 
investigator decision (atosiban), participant decision (atosiban), and other reasons (not stated; 
retosiban). 
Efficacy 
In the placebo-controlled trial, the mean (SD) TTD or treatment failure for retosiban-treated 
participants was 18.9 (22.99) versus 11.1 (14.99) days for placebo. One retosiban-treated 
participant met criteria for treatment failure (received the rescue tocolytic ketorolac 
trometamol). In the placebo group, 4 participants met criteria for treatment failure; of these, 2 
received magnesium sulfate at a rate >2 g/h and 2 received rescue tocolytics (terbutaline and 
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nifedipine). Two (20.0%) neonates in the retosiban group and 4 (30.8%) in the placebo group 
had ≥1 component of the neonatal composite endpoint. In the retosiban group, both infants 
experienced respiratory distress syndrome (RDS). In the placebo group, there was 1 infant 
with RDS, 1 with bronchopulmonary dysplasia, and 2 with RDS and bronchopulmonary 
dysplasia.  
In the placebo-controlled trial, 8 (80.0%) participants in the retosiban group and 9 (69.2%) in 
the placebo group delivered before 37 weeks’ gestation; 2 (20.0%) and 4 (30.8%), 
respectively, delivered at term. The mean (SD) TTD was 19.2 (22.77) days for retosiban-
treated participants versus 16.3 (18.60) days with placebo.  
In the atosiban comparator trial, the adjusted mean (SD) TTD was 32.5 (2.99) days in the 
retosiban group and 33.7 (2.53) days in the atosiban group (P>0.05), with a treatment 
difference of −1.20 days (95% CI −8.879, 6.479; P>0.05) (Figure 3). The mean (SD) times 
from first study treatment dose until delivery, retreatment, or subsequent preterm labor, 
whichever occurred first, were 21.7 (18.55) days (retosiban, n=46) and 24.6 (22.06) days 
(atosiban, n=50). Overall, 25 (54.3%) participants and 28 (56.0%) participants receiving 
retosiban and atosiban, respectively, delivered before 37 weeks’ gestation. Three (6.4%) 
neonates in the retosiban group and 2 (4.0%) in the atosiban group had a diagnosis within the 
composite efficacy endpoint (retosiban, RDS n=3; atosiban, RDS n=1, died n=1). 
Safety 
Maternal, fetal, and neonatal AEs are listed in Supplementary Material 6.  
In the placebo-controlled trial, 6 maternal participants in each treatment group (retosiban 
60.0%; placebo 46.2%) experienced an AE (none serious). There were 5 (50.0%) fetal AEs in 
the retosiban group, 1 of which was serious but likely unrelated to study treatment (umbilical 
cord prolapse), and 3 (23.1%) in the placebo group (none serious). Seven (70.0%) neonates in 
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the retosiban group and 8 (61.5%) in the placebo group had an AE; 5 (50.0%) and 3 (23.1%) 
were considered serious, respectively. Two neonates, 1 per treatment group, experienced 
neonatal RDS-related events not included in the composite endpoint (retosiban: did not meet 
definition of RDS; placebo: captured as an AE but not evaluated for the composite endpoint). 
No AEs led to treatment discontinuation or study withdrawal or were considered study drug 
related. There were no deaths.  
In the atosiban comparator trial, maternal AEs were more frequent with retosiban (n=34 
[72.3%]) than atosiban (n=28 [56.0%]), whereas the frequencies of serious AEs were similar 
between groups (retosiban: n=7 [14.9%]; atosiban: n=9 [18.0%]). Postpartum hemorrhage 
was less common with retosiban (n=1 [2.1%]) than atosiban (n=5 [10.0%]). Three 
participants discontinued treatment because of AEs (retosiban: n=1 maternal [appendicitis], 
n=1 fetal [oligohydramnios]; atosiban: n=1 maternal [abdominal pain]). Fetal AE incidences 
were similar in each group (retosiban n=9 [19.1%], atosiban n=8 [16.0%]) and 6 were serious 
(retosiban n=4, atosiban n=2). The incidences of neonatal AEs (retosiban: 25 [53.2%]; 
atosiban: 26 [52.0%]) and serious AEs (retosiban: 10 [21.3%]; atosiban: 11 [22.0%]) were 
similar between groups. Two infants in the retosiban group and 1 in the atosiban group 
experienced RDS-related events not included in the composite endpoint. No fetal or neonatal 
AEs were considered to be study drug related. Three retosiban-treated and 2 atosiban-treated 
maternal participants experienced AEs considered study drug related.  
There were no maternal or fetal deaths. There was 1 neonatal death (sudden infant death 
syndrome) in the atosiban group, which occurred 39 days after delivery. 
In both trials, there were no clinically important changes in hematologic or biochemical 





The results of pharmacokinetic analyses on a subset of participants receiving retosiban in the 
placebo-controlled trial (n=10) and atosiban comparator trial (n=47) are described in 
Supplementary Material 7.  
Comment 
Principal findings and results 
Due to recruitment challenges, both interventional studies were terminated early. For both 
studies, no new safety signals for retosiban were identified for maternal, fetal, or neonatal 
participants. As the placebo-controlled study completed with 2.6% of the planned enrollment, 
no formal hypothesis testing was conducted on efficacy endpoints, thereby limiting 
conclusions regarding the effectiveness of retosiban compared with placebo. The atosiban 
controlled study completed with 29% of the planned enrollment, and formal hypothesis 
testing demonstrated no statistically significant difference between the atosiban and retosiban 
groups to prolong pregnancy. Since there was no overlap between the centers recruiting for 
each study, and indeed limited overlap in countries involved in each study (Supplementary 
Material 5), we conclude that conducting two studies concurrently was not a factor in low 
participant recruitment. Our efforts to increase recruitment included addition of study sites, 
increasing staff at study sites, and reduction of a requirement for 48-hour continuous fetal 
heart rate monitoring to a minimum of 6 hours if heart rate remained reassuring. 
Clinical and research implications 
Because of early study termination, the clinical implications are limited, apart from the fact 
that retosiban will not be licensed. Clinical practice in the US will continue to use tocolytics 
that are not FDA approved and have limited to no evidence of neonatal benefit. However, 
these studies have broad research implications for future research in this area. 
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The FDA requires placebo-controlled trials that are designed and powered to demonstrate 
neonatal benefit and in which participants receive no other tocolytics.1, 11 The inclusion of a 
placebo arm led to many countries and sites refusing to participate as they considered it 
below standard of care (SoC), even with clinical equipoise.1, 11 Several alternative trial 
designs were proposed to the FDA, including placebo in addition to SoC or versus an active 
comparator (eg, nifedipine). Meetings were held with the FDA, which included key opinion 
leaders in maternal fetal medicine and leaders on clinical trial design, and a clear path was 
provided for how the analysis would be managed to account for the treatment variables. 
These proposals were rejected by the FDA despite precedented use in many therapeutic areas. 
Conversely, add-on and active-control study designs were acceptable to the EMA. 
The low frequency of individual endpoints requires large sample sizes.1 The planned placebo-
controlled trial would have taken >10 years to complete. In the retosiban trials, the sample 
size required to show a meaningful treatment difference in the neonatal composite endpoint 
was a major barrier and led to early study termination. A solution in future trials would be to 
use a composite endpoint, but no standard exists for neonatal morbidity and mortality,1 nor 
are there standardized definitions for some composite endpoint components (eg, RDS) , and 
no regulatory-accepted surrogate endpoint exists.1 Neonatology expertise was utilized when 
developing the composite endpoint for neonatal morbidity used in this study, and background 
rates were estimated using several different databases and literature. There is a need for the 
obstetrics community to develop suitable standardized endpoints.  
These studies also highlight the challenge of accommodating different treatment practices 
and SoC between centers, which made it difficult to design a protocol suitable for all centers 
and acceptable to regulatory agencies. The regulatory agencies required retosiban to be 
trialed in adolescents; however, in 6 countries, ethics committees did not allow this. French 
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investigators did not participate because of the requirement of continuous fetal heart rate 
monitoring during study drug administration.12  
The trials were also complicated by lack of consensus on the definition of sPTL, and differing 
methods used to measure cervical dilation and change. Until differences in diagnostic 
practices between centers and the lack of defined SoC are resolved, these issues will continue 
to impact tocolytic development. 
Strengths and limitations 
The planned placebo-controlled trial would have represented the largest tocolytic study ever 
conducted and would have been one of the few studies to compare a tocolytic against 
placebo. However, the feasibility estimates did not match actual enrollment of participants. 
One limitation was that the complex protocols introduced challenges for participating sites. 
Other limitations were related to regulatory requirements for the study design and have been 
discussed above.  
Conclusions 
These trials demonstrate the multifactorial difficulties encountered in designing and 
conducting clinical trials in sPTL, including a lack of global medical consensus for obstetric 
and neonatal definitions and care, differing regulatory requirements between the US and 
elsewhere, and the lack of a validated composite endpoint for neonatal outcomes. Significant 
cooperation between pharmaceutical companies, regulatory authorities, and the obstetric 
community is required to standardize criteria to assess future tocolytic agents and overcome 
the hurdles inherent to trials in pregnant women. Although a simpler way forward would be 
to conduct regional studies, the number of neonatal events required to show statistical success 
makes this unfeasible; the FDA has rejected the use of a meta-analysis approach, which could 
address this limitation. 
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In 2006, Goodwin reviewed the challenges in tocolytic development and asked whether a true 
placebo-controlled trial can be conducted in a timely fashion.1 The retosiban trials suggest 
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FIGURE 1 Participant disposition in the placebo-controlled trial 
 
ITT, intent-to-treat 
aDefined as completing all stages of the study, including the post-delivery assessment 










FIGURE 2 Participant disposition in the atosiban comparator trial 
 
ITT, intent-to-treat 
aDefined as completing all stages of the study, including the post-delivery assessment 









FIGURE 3 Kaplan–Meier curves of time to delivery in the atosiban comparator trial  
 
One participant in the retosiban group was withdrawn before delivery and was considered 
censored at the last record available in the study database; P-value is retosiban versus 





TABLE 1 Maternal/fetal baseline demographics and clinical characteristics 




















Race, n (%)     
African American/African 2 (20.0) 2 (15.4) 0 3 (6.0) 
American Indian or Alaskan native 0 0 7 (14.9) 4 (8.0) 
Asian 3 (30.0) 6 (46.2) 9 (19.1) 4 (8.0) 
White 5 (50.0) 5 (38.5) 31 (66.0) 39 (78.0) 
Body mass index, mean±SD, kg/m2 26.0±3.60 24.8±4.72 25.6±4.07a 26.4±5.02b 
GA at randomization, mean±SD, week 30.8±2.63 30.5±2.49 31.5±2.13 31.5±2.22 
GA at randomization, n (%)     
240/7 to 256/7 weeks 0 1 (7.7) 2 (4.3) 2 (4.0) 
260/7 to 276/7 weeks 2 (20.0) 1 (7.7) 0 1 (2.0) 
280/7 to 306/7 weeks 3 (30.0) 4 (30.8) 13 (27.7) 12 (24.0) 




GA, gestational age; SD, standard deviation  








Contractions per 30 minutes, median (range), 
n 
6 (4−9) 7 (4−17) 7 (3−20) 7 (4−16) 
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TABLE 2 Neonatal birth record  
Characteristic 
 





































Apgar score 1 minute after 









Apgar score 5 minutes after 









an=46; bn=49; cn=43; dn=42 
GA, gestational age; SD, standard deviation  
 
